LIVIVO - Search results -

Search results

Result 1 - 10 of total 111

Search options

Article ; Online: Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies.

Duléry, Rémy / Brissot, Eolia / Mohty, Mohamad

2023 Volume 62, Page(s) 101080

Abstract: In search of an ideal partner or alternative to conventional immunosuppressive agents, rabbit anti-thymocyte globulin (ATG) and, more recently, post-transplant cyclophosphamide (PT-Cy) have both emerged as valid and efficient options for preventing graft- ...

Abstract	In search of an ideal partner or alternative to conventional immunosuppressive agents, rabbit anti-thymocyte globulin (ATG) and, more recently, post-transplant cyclophosphamide (PT-Cy) have both emerged as valid and efficient options for preventing graft-versus-host disease (GvHD). To further reduce the risk of GvHD, strategies combining ATG and PT-Cy have recently been investigated. In a haploidentical setting, retrospective studies suggest that combining PT-Cy and ATG may result in a lower incidence of chronic GvHD without increasing the risks of infection or relapse, when compared to PT-Cy without ATG. In haploidentical or unrelated donor settings, adding reduced doses of PT-Cy to ATG may reduce the risk of acute and chronic GvHD and improve survival, particularly GvHD-free, relapse-free survival (GRFS), when compared to ATG without PT-Cy. Overall, the combination of PT-Cy and ATG is a safe and promising approach for patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
MeSH term(s)	Humans ; Antilymphocyte Serum/therapeutic use ; Retrospective Studies ; Neoplasm Recurrence, Local/drug therapy ; Cyclophosphamide/therapeutic use ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Hematologic Neoplasms/therapy ; Hematologic Neoplasms/drug therapy ; Bronchiolitis Obliterans Syndrome ; Hematopoietic Stem Cell Transplantation/adverse effects ; Transplantation Conditioning
Chemical Substances	Antilymphocyte Serum ; Cyclophosphamide (8N3DW7272P)
Language	English
Publishing date	2023-04-11
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	639015-8
ISSN	1532-1681 ; 0268-960X
ISSN (online)	1532-1681
ISSN	0268-960X
DOI	10.1016/j.blre.2023.101080
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2207: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives.

Abou Dalle, Iman / Dulery, Remy / Moukalled, Nour / Ricard, Laure / Stocker, Nicolas / El-Cheikh, Jean / Mohty, Mohamad / Bazarbachi, Ali

Blood cancer journal

2024 Volume 14, Issue 1, Page(s) 23

Abstract: Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell ... ...

Abstract	Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives.
MeSH term(s)	Humans ; Hematopoietic Stem Cell Transplantation ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Transplantation, Autologous ; Lymphoma, Non-Hodgkin/drug therapy ; Lymphoma, B-Cell/drug therapy ; Salvage Therapy
Language	English
Publishing date	2024-01-25
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2600560-8
ISSN	2044-5385 ; 2044-5385
ISSN (online)	2044-5385
ISSN	2044-5385
DOI	10.1038/s41408-024-00989-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Introduction to medical data and big data exploitation in research: Errors, solutions and trends.

Alsuliman, Tamim / Humaidan, Dania / Sliman, Layth / Duléry, Rémy

Current research in translational medicine

2021 Volume 69, Issue 4, Page(s) 103310

MeSH term(s)	Big Data ; Humans
Language	English
Publishing date	2021-08-19
Publishing country	France
Document type	Editorial
ISSN	2452-3186
ISSN (online)	2452-3186
DOI	10.1016/j.retram.2021.103310
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Autologous hematopoietic cell transplantation as a part of a sequential multi-phase therapeutic approach (R-COPADM/CYVE/ASCT) as first-line treatment of high-grade B-cell lymphoma: results of a retrospective study with long-term follow-up.

Alsuliman, Tamim / Stocker, Nicolas / Corre, Elise / Dulery, Rémy / Sestili, Simona / Ricard, Laure / Malard, Florent / Mohty, Mohamad / Coppo, Paul / Marjanovic, Zora

Bone marrow transplantation

2022 Volume 58, Issue 4, Page(s) 437–439

Abstract: Patients with high-risk lymphoma have a poor prognosis when treated with standard chemoimmunotherapy. This retrospective study included 23 high-risk lymphoma patients with a median age at diagnosis of 59 (range, 35-68) years. They received 2 cycles of R- ... ...

Abstract	Patients with high-risk lymphoma have a poor prognosis when treated with standard chemoimmunotherapy. This retrospective study included 23 high-risk lymphoma patients with a median age at diagnosis of 59 (range, 35-68) years. They received 2 cycles of R-COPADM and 2 cycles of CYVE, completed by ASCT for fit patients. With a median follow-up of 46 (range, 3-78) months, three (13%) patients in the cohort died. Nearly half of the patients had an ECOG performance status of 2 or 3. Most patients in the cohort (91%, n = 21) had Ann Arbor stage III-IV disease, and 88% (n = 20) had an IPI of 3 to 5. LDH levels were elevated in 83% (n = 19) of patients. Overall, 30% of patients were identified as having double-expressor lymphoma and 22% as having DHL, while two patients (9%) had THL. The origin of the lymphoma was GC B-cell-like in 15 patients (65%) and ABC-like in 8 patients (35%). Cumulative incidence of relapse at 46 months was 14% (95% CI, 5-37), while overall survival was 87% (95% CI, 64-95) and progression-free survival was 83% (95% CI, 60-93). These results showed the efficacy and an acceptable safety profile of the R-COPADM/CYVE/ASCT regimen in high-risk lymphoma, including patients with DHL.
MeSH term(s)	Humans ; Adult ; Middle Aged ; Aged ; Follow-Up Studies ; Retrospective Studies ; Disease-Free Survival ; Neoplasm Recurrence, Local ; Hematopoietic Stem Cell Transplantation/methods ; Lymphoma, B-Cell/therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Transplantation, Autologous ; Lymphoma
Language	English
Publishing date	2022-12-22
Publishing country	England
Document type	Letter
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-022-01902-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.

Brissot, Eolia / Labopin, Myriam / Labussière, Helene / Fossard, Gaelle / Chevallier, Patrice / Guillaume, Thierry / Yakoub-Agha, Ibrahim / Srour, Micha / Bulabois, Claude-Eric / Huynh, Anne / Chantepie, Sylvain / Menard, Anne-Lise / Rubio, Marie-Therese / Ceballos, Patrice / Dulery, Rémy / Furst, Sabine / Malard, Florent / Blaise, Didier / Mohty, Mohamad

Blood cancer journal

2024 Volume 14, Issue 1, Page(s) 31

Abstract: The use of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis is not established after reduced intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) from fully matched donors. This was a ... ...

Abstract	The use of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis is not established after reduced intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) from fully matched donors. This was a randomized, open-label, multicenter, phase 2 trial. All patients received a RIC regimen with fludarabine, intravenous busulfan for 2 days (Flu-Bu2), and a peripheral blood stem cell (PBSC) graft from a matched related or 10/10 HLA-matched unrelated donor. Patients were randomly assigned to receive anti-thymocyte globulin (ATG) 5 mg/kg plus standard GVHD prophylaxis or PTCy 50 mg/kg/d at days +3 and +4 plus standard GVHD prophylaxis. The primary endpoint was the composite endpoint of GVHD- and relapse-free survival (GRFS) at 12 months after HSCT. Eighty-nine patients were randomly assigned to receive either PTCy or control prophylaxis with ATG. At 12 months, disease-free survival was 65.9% in the PTCy group and 67.6% in the ATG group (P = 0.99). Cumulative incidence of relapse, non-relapse mortality, and overall survival were also comparable in the two groups. GRFS at 12 months was 54.5% in the PTCy group versus 43.2% in the ATG group (P = 0.27). The median time to neutrophil and platelet count recovery was significantly longer in the PTCy group compared to the ATG group. Except for day +30, where EORTC QLQ-C30 scores were significantly lower in the PTCy compared to the ATG group, the evolution with time was not different between the two groups. Although the primary objective was not met, PTCy is effective for GVHD prophylaxis in patients receiving Flu-Bu2 conditioning with a PBSC graft from a fully matched donor and was well tolerated in term of adverse events and quality of life. This trial was registered at clinicaltrials.gov: NCT02876679.
MeSH term(s)	Humans ; Antilymphocyte Serum/therapeutic use ; Unrelated Donors ; Siblings ; Quality of Life ; Cyclophosphamide/therapeutic use ; Hematopoietic Stem Cell Transplantation/adverse effects ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Retrospective Studies
Chemical Substances	Antilymphocyte Serum ; Cyclophosphamide (8N3DW7272P)
Language	English
Publishing date	2024-02-19
Publishing country	United States
Document type	Randomized Controlled Trial ; Multicenter Study ; Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2600560-8
ISSN	2044-5385 ; 2044-5385
ISSN (online)	2044-5385
ISSN	2044-5385
DOI	10.1038/s41408-024-00990-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Villar, Sara / Chevret, Sylvie / Poire, Xavier / Joris, Magalie / Chevallier, Patrice / Bourhis, Jean-Henri / Forcade, Edouard / Chantepie, Sylvain / Beauvais, David / Raus, Nicole / Bay, Jacques-Olivier / Loschi, Michael / Devillier, Raynier / Duléry, Remy / Ceballos, Patrice / Rubio, Marie Thérèse / Servais, Sophie / Nguyen, Stephanie / Robin, Marie

Bone marrow transplantation

2024

Abstract: In this SFGM-TC registry study, we report the results after stem cell transplantation (HSCT) in 305 myelofibrosis patients, in order to determine potential risk factors associated with outcomes, especially regarding previous treatment with ruxolitinib. A ...

Abstract	In this SFGM-TC registry study, we report the results after stem cell transplantation (HSCT) in 305 myelofibrosis patients, in order to determine potential risk factors associated with outcomes, especially regarding previous treatment with ruxolitinib. A total of 102 patients were transplanted from an HLA-matched-sibling donor (MSD), and 143 patients received ruxolitinib. In contrast with previous studies, our results showed significantly worse outcomes for ruxolitinib patients regarding overall survival (OS) and non-relapse mortality (NRM), especially in the context of unrelated donors (URD). When exploring reasons for potential confounders regarding the ruxolitinib effect, an interaction between the type of donor and the use of ATG was found, therefore subsequent analyses were performed separately for each type of donor. Multivariable analyses did not confirm a significant negative impact of ruxolitinib in transplantation outcomes. In the setting of URD, only age and Fludarabine-Melphalan (FM) conditioning were associated with increased NRM. For MSD, only Karnoksfy <70% was associated with reduced OS. However, a propensity score analysis showed that ruxolitinib had a negative impact on OS but only in non-responding patients, consistent with previous data. To conclude, with all the precautions due to confounders and bias, ruxolitinib itself does not appear to increase mortality after HSCT.
Language	English
Publishing date	2024-03-21
Publishing country	England
Document type	Journal Article
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-024-02268-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Microbiota dysbiosis after high-dose melphalan and autologous hematopoietic cell transplantation in multiple myeloma.

Malard, Florent / Battipaglia, Giorgia / Gaugler, Béatrice / Siblany, Lama / van de Wyngaert, Zoe / Bonnin, Agnes / Duléry, Rémy / Banet, Anne / Stocker, Nicolas / Ricard, Laure / Brissot, Eolia / Mohty, Mohamad

Bone marrow transplantation

2023 Volume 58, Issue 11, Page(s) 1275–1278

MeSH term(s)	Humans ; Melphalan/adverse effects ; Multiple Myeloma/therapy ; Dysbiosis ; Hematopoietic Stem Cell Transplantation ; Transplantation, Autologous ; Transplantation Conditioning/adverse effects
Chemical Substances	Melphalan (Q41OR9510P)
Language	English
Publishing date	2023-08-22
Publishing country	England
Document type	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-023-02078-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study.

El Cheikh, Jean / Bidaoui, Ghassan / Atoui, Ali / Terro, Khodr / Sharrouf, Layal / Zahreddine, Ammar / Moukalled, Nour / Abou Dalle, Imane / Bazarbachi, Ali / Mohty, Mohamad / Dulery, Remy

Bone marrow transplantation

2023 Volume 58, Issue 6, Page(s) 667–672

Abstract: Clofarabine (Clo) is an immunosuppressive purine analog that may have better anti-leukemic activity than fludarabine (Flu). The addition of total body irradiation (TBI) to conditioning regimens has been widely investigated. However, the use of single ... ...

Abstract	Clofarabine (Clo) is an immunosuppressive purine analog that may have better anti-leukemic activity than fludarabine (Flu). The addition of total body irradiation (TBI) to conditioning regimens has been widely investigated. However, the use of single agent Clo in combination with intermediate doses of TBI ranging from 4 to 8 Gy has not been studied yet. This study is a double center, observational, retrospective study of patients with high-risk hematological malignancies diagnosed from 2012 to 2021, treated at the American University of Beirut Medical Center in Beirut (AUBMC), Lebanon, and Saint-Antoine Hospital (SAH) in Paris, France. It aims to identify the outcome of patients with high-risk hematological malignancies who underwent allogeneic stem cell transplant (allo-SCT) and received Clo and TBI (4-8 Gy) before transplant. Data regarding patient baseline characteristics, disease-related factors, and transplant outcomes including graft-versus-host disease (GVHD), Non-relapse mortality (NRM), progression-free survival (PFS), and overall survival (OS), were collected. We identified 24 high-risk patients diagnosed with a hematological malignancy. The median age at transplant was 37 years (range 22-78). At the time of the transplant, only 15 patients (63%) were in complete remission (CR). All patients received Clo/TBI (4-8 Gy). After a median follow-up of 40 months, the cumulative incidences of grade II-III acute GVHD, grade IV acute GVHD, and chronic GVHD were 50%, 4%, and 8%, respectively. NRM at 100 days, and 1 year after transplant was 4% and 25%, respectively. 17% of the patients had a relapse or progression of the disease by the end of the study. The 2-year PFS and OS were 50% and 56%, respectively. The median PFS and OS were 66 and 68 months respectively. As a conclusion, Clo/TBI (4-8 Gy) as a conditioning regimen for allo-SCT in high-risk patients confers disease control with an acceptable toxicity profile.
MeSH term(s)	Humans ; Young Adult ; Adult ; Middle Aged ; Aged ; Clofarabine/pharmacology ; Retrospective Studies ; Whole-Body Irradiation/adverse effects ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hematologic Neoplasms/therapy ; Graft vs Host Disease/etiology ; Leukemia ; Transplantation Conditioning/adverse effects
Chemical Substances	Clofarabine (762RDY0Y2H)
Language	English
Publishing date	2023-03-13
Publishing country	England
Document type	Observational Study ; Journal Article
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-023-01947-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies.

Mohty, Razan / Dulery, Rémy / Bazarbachi, Abdul Hamid / Savani, Malvi / Hamed, Rama Al / Bazarbachi, Ali / Mohty, Mohamad

Blood cancer journal

2021 Volume 11, Issue 7, Page(s) 126

Abstract: Hodgkin lymphoma is a highly curable disease. Although most patients achieve complete response following frontline therapy, key unmet clinical needs remain including relapsed/refractory disease, treatment-related morbidity, impaired quality of life and ... ...

Abstract	Hodgkin lymphoma is a highly curable disease. Although most patients achieve complete response following frontline therapy, key unmet clinical needs remain including relapsed/refractory disease, treatment-related morbidity, impaired quality of life and poor outcome in patients older than 60 years. The incorporation of novel therapies, including check point inhibitors and antibody-drug conjugates, into the frontline setting, sequential approaches, and further individualized treatment intensity may address these needs. We summarize the current treatment options for patients with classical Hodgkin lymphoma from frontline therapy to allogeneic hematopoietic stem cell transplantation and describe novel trials in the field.
MeSH term(s)	Antineoplastic Agents, Immunological/therapeutic use ; Disease Management ; Hematopoietic Stem Cell Transplantation ; Hodgkin Disease/therapy ; Humans ; Immunoconjugates/therapeutic use ; Quality of Life ; Transplantation, Homologous
Chemical Substances	Antineoplastic Agents, Immunological ; Immunoconjugates
Language	English
Publishing date	2021-07-09
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2600560-8
ISSN	2044-5385 ; 2044-5385
ISSN (online)	2044-5385
ISSN	2044-5385
DOI	10.1038/s41408-021-00518-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.

Savani, Malvi / Dulery, Rémy / Bazarbachi, Abdul Hamid / Mohty, Razan / Brissot, Eolia / Malard, Florent / Bazarbachi, Ali / Nagler, Arnon / Mohty, Mohamad

British journal of haematology

2021 Volume 195, Issue 4, Page(s) 495–506

Abstract: Myelofibrosis (MF) is a clonal stem cell neoplasm with heterogeneous clinical phenotypes and well-established molecular drivers. Allogeneic haematopoietic stem cell transplantation (HSCT) offers an important curative treatment option for primary MF and ... ...

Abstract	Myelofibrosis (MF) is a clonal stem cell neoplasm with heterogeneous clinical phenotypes and well-established molecular drivers. Allogeneic haematopoietic stem cell transplantation (HSCT) offers an important curative treatment option for primary MF and post-essential thrombocythaemia/polycythaemia vera MF or secondary MF. With a disease course that varies from indolent to highly progressive, we are now able to stratify risk of mortality through various tools including patient-related clinical characteristics as well as molecular genetic profile. Owing to the high risk of mortality and morbidity associated with HSCT for patients with myelofibrosis, it is important to improve patient selection for transplant. Our primary goal is to comprehensively define our understanding of current practices including the role of Janus Kinase (JAK) inhibitors, to present the data behind transplantation before and after leukaemic transformation, and to introduce novel personalization of MF treatment with a proposed clinical-molecular prognostic model to help elucidate a timepoint optimal for consideration of HSCT.
MeSH term(s)	Allografts ; Clinical Trials as Topic ; Combined Modality Therapy ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/therapeutic use ; Disease Progression ; Donor Selection ; Hematopoiesis, Extramedullary ; Hematopoietic Stem Cell Transplantation ; Humans ; Janus Kinase 2/antagonists & inhibitors ; Janus Kinase 2/genetics ; Middle Aged ; Mutation ; Nitriles/administration & dosage ; Nitriles/therapeutic use ; Premedication ; Primary Myelofibrosis/drug therapy ; Primary Myelofibrosis/genetics ; Primary Myelofibrosis/surgery ; Primary Myelofibrosis/therapy ; Prognosis ; Protein Kinase Inhibitors/therapeutic use ; Pyrazoles/administration & dosage ; Pyrazoles/therapeutic use ; Pyrimidines/administration & dosage ; Pyrimidines/therapeutic use ; Recurrence ; Risk Assessment ; Salvage Therapy ; Severity of Illness Index ; Splenectomy ; Transplantation Conditioning/methods
Chemical Substances	Nitriles ; Protein Kinase Inhibitors ; Pyrazoles ; Pyrimidines ; ruxolitinib (82S8X8XX8H) ; Cyclophosphamide (8N3DW7272P) ; JAK2 protein, human (EC 2.7.10.2) ; Janus Kinase 2 (EC 2.7.10.2)
Language	English
Publishing date	2021-04-21
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/bjh.17469
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito